Abstract: The present invention relates to compounds that bind to prostate-specific membrane antigen (PSMA) comprising a PSMA binding moiety, a linker group comprising a silicon-fluoride acceptor (SIFA) moiety and a chelator moiety, optionally containing a chelated nonradioactive or radioactive cation, wherein the SIFA moiety comprises a covalent bond between a silicon and a fluorine atom which can be 18F. The disclosure includes compounds of Formula (1) or a pharmaceutically acceptable salt or any individual isomer thereof, wherein CM is defined herein, and their use as cancer diagnostic or imaging agents.

Abstract: Provided is a ligand compound, comprising (a) a targeting group, (b) one or more chelating groups, optionally containing a chelated radioactive or non-radioactive cation, and (c) a group carrying an Si—OH functional moiety. The ligand compound is suitable for use in therapeutic or diagnostic methods, especially in radiotherapy or radiodiagnosis of cancer, such as prostate cancer.